*仅供医学专业人士阅读参考看多了人体内各种细胞争先恐后给癌细胞当帮凶的研究，奇点糕总有种误入了某全员内鬼酒厂，啊不组织的感觉，哪天真跳出来个助力抗癌的“正面人物”，奇点糕都得看着论文标题愣一下才敢相信，这叫什么个事儿啊。不过奇点糕的这种刻板印象其实也 ...

前列腺癌（Prostate cancer, PCa）是威胁中老年男性健康的主因之一。在2024年全球男性肿瘤发病率和死亡率统计中，PCa分别排第二和第五位[1]。雄激素和雄激素受体（Androgen ...

2024年9月4日，上海交通大学生物医学工程学院夏伟梁团队和上海交通大学医学院附属胸科医院陆舜团队合作在 Science Translational Medicine 上发表了题为PTPRT loss enhances anti-PD-1 therapy efficacy by regulation of STING pathway in non-small cell lung cancer ...

在本研究中，研究人员先是通过分析TCGA数据库，确认了 Sdc1 的确会在多种肿瘤中表达上调，且其表达上调与不良预后有关。随后研究人员想知道，敲除 Sdc1 对 肿瘤细胞 增殖的影响。

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

Phase III data presented at the WCLC suggests the new VEGF and PD-L1 inhibitor could prolong progression-free survival versus Merck's anti-PD-1 blockbuster.

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...

Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding novel agents to perioperative durvalumab (Imfinzi ...

Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq1,2New subcutaneous (SC) op ...